Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Provita Centrum Medyczne Sp. z o.o.

Verified siteinfo

Poland Ul. Jana Pawla II 35, 97-200 Tomaszow Mazowiecki, Poland

  • 7 trials recruiting
  • Non-small cell lung cancer · HER2 mutant non-small cell lung cancer · Non-small cell lung cancer metastatic
  • Adult patients

About Specializations

Provita Centrum Medyczne Sp. z o.o. in Tomaszow Mazowiecki, Poland specialises in clinical trials of conditions such as Non-small cell lung cancer, HER2 mutant non-small cell lung cancer, Non-small cell lung cancer metastatic, Non-small cell lung cancer stage III, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms – Oncology Research

Provita Centrum Medyczne is conducting focused oncology trials aimed at improving outcomes for patients with advanced cancers. The studies evaluate novel pembrolizumab and nivolumab based immunotherapy combinations, as well as enzalutamide strategies, to extend overall survival and delay disease progression in metastatic castration‑resistant prostate cancer and non‑small cell lung cancer.

  • Metastatic castration‑resistant prostate cancer
  • Previously untreated locally advanced non‑small cell lung cancer
  • Combination of checkpoint inhibitors with androgen receptor blockade
  • Assessment of progression‑free and overall survival

The eight investigators at this hospital‑clinic collaborate to bring cutting‑edge cancer research to Tomaszów Mazowiecki, Poland.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Jana Pawla II 3597-200 Tomaszow MazowieckiPoland
Open in maps ↗
Recruiting now
7 trials
Conditions studied
16
Partner status
Verified site

More sites in Tomaszow MazowieckiPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

10 clinical trials

Squamous cell carcinoma of lung+4

Recruiting

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Pfizer Inc.

Squamous cell carcinoma of lung+8

Recruiting

A study testing BNT326 and BNT327 with drug combination for safety and effectiveness in people with advanced non-small cell lung cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BNT326
  • Sponsor:BioNTech SE

Non-small cell lung cancer

Recruiting

A Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Non-small cell lung cancer

Recruiting

A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Pfizer Inc.

Clear cell renal cell carcinoma

Recruiting

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AB521
  • Sponsor:Arcus Biosciences Inc.

Non-small cell lung cancer+1

Recruiting

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Small cell lung cancer

Recruiting

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.

Breast cancer+3

Not recruiting

Study of romiplostim for treating low platelet counts caused by chemotherapy in adults with non-small cell lung cancer, ovarian cancer, or breast cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Romiplostim
  • Sponsor:Amgen Inc.

Hormone-refractory prostate cancer+1

Not recruiting

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer stage III

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Stage 3 Non-Small Cell Lung Cancer Not Suitable for Surgery

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol Myers Squibb International Corporation
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.